Targeting survivin in cancer therapy
- 18 March 2008
- journal article
- review article
- Published by Informa Healthcare in Emerging Therapeutic Targets
- Vol. 12 (4), 463-476
- https://doi.org/10.1517/14728222.12.4.463
Abstract
(2008). Targeting survivin in cancer therapy. Expert Opinion on Therapeutic Targets: Vol. 12, No. 4, pp. 463-476.Keywords
This publication has 121 references indexed in Scilit:
- Forced Expression of Survivin-2B Abrogates Mitotic Cells and Induces Mitochondria-dependent Apoptosis by Blockade of Tubulin Polymerization and Modulation of Bcl-2, Bax, and SurvivinJournal of Biological Chemistry, 2007
- Compartmentalized Phosphorylation of IAP by Protein Kinase A Regulates CytoprotectionMolecular Cell, 2007
- Targeting survivin in cancer therapy: fulfilled promises and open questionsCarcinogenesis: Integrative Cancer Research, 2007
- The Survivin–Crm1 interaction is essential for chromosomal passenger complex localization and functionEMBO Reports, 2006
- Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the familyEMBO Reports, 2006
- Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonistOncogene, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Cancer genes and the pathways they controlNature Medicine, 2004
- Survivin, versatile modulation of cell division and apoptosis in cancerOncogene, 2003
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999